MedTrace Logo

A Study of ALS-008176 in Infants Hospitalized With RSV

NCT02202356 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2025-02-03

No results posted yet for this study

Summary

This study will assess the safety, tolerability, pharmacokinetics (PK) and anti-viral effect of single and multiple doses of ALS-008176 in infants hospitalized with respiratory syncytial virus (RSV)

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

DRUG

ALS-008176

DRUG

Placebo

Sponsors & Collaborators

  • Alios Biopharma Inc.

    lead INDUSTRY

Principal Investigators

  • Matthew McClure, M.D. · Alios BioPharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-23
Primary Completion
2018-02-15
Completion
2018-02-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Chile
  • Colombia
  • France
  • Japan
  • New Zealand
  • Panama
  • Romania
  • South Africa
  • Taiwan
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02202356 on ClinicalTrials.gov